Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
    Hayashida, Tetsu
    Jinno, Hiromitsu
    Mori, Katsuaki
    Sato, Hiroki
    Matsui, Akira
    Sakurai, Takashi
    Hattori, Hiroaki
    Takayama, Shin
    Wada, Masahiro
    Takahashi, Maiko
    Seki, Hirohito
    Seki, Tomoko
    Nagayama, Aiko
    Matsumoto, Akiko
    Kitagawa, Yuko
    BMC CANCER, 2018, 18
  • [2] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
    Takashima, Tsutomu
    Tokunaga, Shinya
    Tei, Seika
    Nishimura, Shigehiko
    Kawajiri, Hidemi
    Kashiwagi, Shinichiro
    Yamagata, Shigehito
    Noda, Satoru
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    SPRINGERPLUS, 2016, 5 : 1 - 8
  • [3] First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepitheliomalikecarcinoma: A Multicenter, Single-Arm, Phase II Trial
    Zhou, C.
    Lin, X.
    Li, S.
    Sun, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S96 - S97
  • [4] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kimura, Kosei
    Iwamoto, Mitsuhiko
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
  • [5] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kosei Kimura
    Mitsuhiko Iwamoto
    Satoru Tanaka
    Daigo Yamamoto
    Katsuhide Yoshidome
    Hiroyuki Ogura
    Risa Terasawa
    Nobuki Matsunami
    Yuko Takahashi
    Toshikatsu Nitta
    Takashi Morimoto
    Hiroya Fujioka
    Kanako Kawaguchi
    Kazuhisa Uchiyama
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
  • [6] Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer
    Iwamoto, Mitsuhiko
    Sato, Nayuko
    Terasawa, Rise
    Fujioka, Hiroya
    Takahashi, Yuko
    Kimura, Kasai
    Tanaka, Satoru
    Uchiyama, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)
    Peer, Avivit
    Neumann, Avivit
    Keizrnan, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [8] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
    Peer, Avivit
    Neumann, Avivit
    Keizman, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A single-arm, phase II, multicenter trial of sunitinib maleate (SU) in locally advanced or metastatic
    Leibowitz-Amit, Raya
    Joshua, Anthony Michael
    Ezzat, Shereen
    Bourdeau, Isabelle
    Olney, Harold
    Oosting, Sjoukje
    Ruether, Joseph D.
    Chin, Soo
    Palmieri, Cristina
    Seah, Jo-An
    Assa, Sylvia L.
    Krzyzanowska, Monika
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] A phase II, multicenter, single-arm study of eribulin mesilate as first-line therapy for HER2-negative locally advanced or metastatic breast cancer.
    Tei, Seika
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Kawajiri, Hidemi
    Tokunaga, Shinya
    Nishimura, Shigehiko
    Yamagata, Shigehito
    Nishimori, Takeo
    Mizuyama, Yoko
    Sunami, Tsuyoshi
    Tezuka, Kenji
    Noda, Satoru
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Onoda, Naoyoshi
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345